Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4875970 | 0.99 | AOC3 (0.60) | AOC3SMN1; SMN2RXFP1DYRK1AITGB3 | |
| SCHEMBL14019606 | 0.95 | AOC3 (0.53) | AOC3SMN1; SMN2RXFP1DYRK1AITGB3 | |
| Hydrochloric Acid SCHEMBL4869579 | 0.94 | AOC3 (0.54) | AOC3SMN1; SMN2RXFP1DYRK1AITGB3 | |
| SCHEMBL15291388 | 0.91 | AOC3 (0.61) | AOC3RXFP1 | |
| SCHEMBL14019550 | 0.90 | AOC3 (0.74) | AOC3 | |
| SCHEMBL14019537 | 0.89 | AOC3 (0.72) | AOC3RXFP1 | |
| SCHEMBL4874901 | 0.89 | AOC3 (0.58) | AOC3SMN1; SMN2RXFP1 | |
| SCHEMBL14019551 | 0.89 | AOC3 (0.57) | AOC3 | |
| Hydrochloric Acid SCHEMBL4875863 | 0.89 | AOC3 (0.74) | AOC3 | |
| SCHEMBL14044988 | 0.88 | AOC3 (0.60) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885SMN1; SMN2 3771/4885RXFP1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.